Study Summary
This trial tests a new drug, MYTX-011, to treat advanced lung cancer. MYTX-011 is an antibody drug conjugate composed of an anti-cMET antibody and an antimicrotubule drug.
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer (Stage IV)
- Non-small Cell Lung Cancer Stage IIIB
- Squamous Non-Small Cell Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 6 Secondary · Reporting Duration: 2 years
Trial Safety
Safety Progress
Trial Design
6 Treatment Groups
Part 2 Cohort B
1 of 6
Part 2 Cohort D
1 of 6
Part 2 Cohort C
1 of 6
Part 2 Cohort E
1 of 6
Part 1 Dose Escalation
1 of 6
Part 2 Cohort A
1 of 6
Experimental Treatment
150 Total Participants · 6 Treatment Groups
Primary Treatment: Part 2 Cohort B · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants are enrolled in this experiment?
"Affirmative. The details hosted on the clinicaltrials.gov website indicate that this experiment is actively recruiting participants, with 150 individuals sought from a single site. This trial was first posted on March 1st 2023 and updated most recently on February 8th 2023." - Anonymous Online Contributor
Has the FDA granted its blessing to Part 2 Cohort E?
"Our research team at Power judged the safety of Part 2 Cohort E to be a 1, as this is an early-phase trial which has not yet provided sufficient evidence regarding its efficacy and safety." - Anonymous Online Contributor
Are there any openings remaining to join this research endeavor?
"Affirmative, information on clinicaltrials.gov attests to the fact that this medical trial is actively recruiting patients. The investigation was first made available on March 1st 2023 and has been recently updated on February 8th 2023. A total of 150 participants are needed from a single site." - Anonymous Online Contributor
What therapeutic objectives have been identified for this clinical trial?
"This trial will evaluate the primary outcome, number of patients with tumor response, over a 21-day period. Secondary endpoints encompass anti-drug antibodies (ADA), duration of response in those that achieve complete or partial responses (DOR), time to response (TTR), disease control rate (DCR) and progression free survival (PFS)." - Anonymous Online Contributor